Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit-Reference-Cited by-同舟云学术

Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit

Published:2008-05-22 Issue:12 Volume:51 Page:3353-3356
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ippolito Joseph A.¹,Kanyo Zoltan F.¹,Wang Deping¹,Franceschi Francois J.¹,Moore Peter B.¹,Steitz Thomas A.¹,Duffy Erin M.¹

Affiliation:

1. Department of Structure-Based Drug Design, Rib-X Pharmaceuticals Inc., 300 George Street, Suite 301, New Haven, Connecticut 06511, and Departments of Molecular Biophysics and Biochemistry and of Chemistry, Yale University, New Haven, Connecticut 06511

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm800379d

Reference29 articles.

1. Linezolid: The First Oxazolidinone Antimicrobial

2. Update on linezolid: the first oxazolidinone antibiotic

3. Oxazolidinones: activity, mode of action, and mechanism of resistance

4. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom

5. Linezolid resistance in a clinical isolate of Staphylococcus aureus

Cited by 256 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents against Drug-Resistant Pathogens;Journal of Medicinal Chemistry;2024-09-05

2. Synthesis and Antibacterial Activities of Linezolid Analogues with C₅‐thioether/N,S‐acetal Amide;ChemistrySelect;2024-08-06

3. Small Molecule Targeting PPM1A Activates Autophagy for Mycobacterium tuberculosis Host-Directed Therapy;Journal of Medicinal Chemistry;2024-07-03

4. Prediction of 3D RNA Structures from Sequence Using Energy Landscapes of RNA Dimers: Application to RNA Tetraloops;Journal of Chemical Theory and Computation;2024-05-10

5. Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities;ACS Infectious Diseases;2024-04-06